HRP20151091T1 - UPORABA 24-norUDCA - Google Patents
UPORABA 24-norUDCA Download PDFInfo
- Publication number
- HRP20151091T1 HRP20151091T1 HRP20151091TT HRP20151091T HRP20151091T1 HR P20151091 T1 HRP20151091 T1 HR P20151091T1 HR P20151091T T HRP20151091T T HR P20151091TT HR P20151091 T HRP20151091 T HR P20151091T HR P20151091 T1 HRP20151091 T1 HR P20151091T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutically acceptable
- acceptable salts
- ursodeoxycholic acid
- cholangiocarcinoma
- prevention
- Prior art date
Links
- QYYDXDSPYPOWRO-JHMCBHKWSA-N (3r)-3-[(3r,5s,7s,8r,9s,10s,13r,14s,17r)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]butanoic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CC(O)=O)C)[C@@]2(C)CC1 QYYDXDSPYPOWRO-JHMCBHKWSA-N 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
- Oscillators With Electromechanical Resonators (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Claims (3)
1. Nor-ursodeoksikolna kiselina i/ili njezine farmaceutski prihvatljive soli, naznačene time, da se upotrebljavaju za liječenje i/ili prevenciju hepatocelularnog karcinoma i kolangiokarcinoma.
2. Nor-ursodeoksikolna kiselina i/ili njezine farmaceutski prihvatljive soli, koje se upotrebljavaju za liječenje i/ili prevenciju hepatocelularnog karcinoma i kolangiokarcinoma, prema zahtjevu 1, naznačene time, da su nor-ursodeoksikolna kiselina i/ili njezine farmaceutski prihvatljive soli, formulirane za oralnu, parenteralnu, subkutanu, intravenoznu, intramuskularnu, nazalnu, topikalnu ili rektalnu primjenu.
3. Nor-ursodeoksikolna kiselina i/ili njezine farmaceutski prihvatljive soli, koje se upotrebljavaju za liječenje i/ili prevenciju hepatocelularnog karcinoma i kolangiokarcinoma, prema zahtjevima 1 ili 2, naznačene time, da se nor-ursodeoksikolna kiselina i/ili njezine farmaceutski prihvatljive soli, primjenjuju na pacijentu u dnevnoj količini od 25 mg do 5 g, poželjno od 100 mg do 2,5 g, posebno od 800 mg do 1,5 g.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2005/052178 WO2006119803A1 (en) | 2005-05-12 | 2005-05-12 | USE OF 24-nor-UDCA |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20151091T1 true HRP20151091T1 (hr) | 2015-11-06 |
Family
ID=35457032
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20150949TT HRP20150949T1 (hr) | 2005-05-12 | 2015-09-08 | UPORABA 24-norUDCA |
| HRP20151091TT HRP20151091T1 (hr) | 2005-05-12 | 2015-10-16 | UPORABA 24-norUDCA |
| HRP20161197TT HRP20161197T1 (hr) | 2005-05-12 | 2016-09-19 | 24-norudca za liječenje autoimunog hepatitisa |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20150949TT HRP20150949T1 (hr) | 2005-05-12 | 2015-09-08 | UPORABA 24-norUDCA |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20161197TT HRP20161197T1 (hr) | 2005-05-12 | 2016-09-19 | 24-norudca za liječenje autoimunog hepatitisa |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US8951995B2 (hr) |
| EP (4) | EP2392335B1 (hr) |
| AU (1) | AU2005331734B2 (hr) |
| CY (4) | CY1116831T1 (hr) |
| DK (4) | DK2392337T3 (hr) |
| EA (1) | EA014077B1 (hr) |
| ES (4) | ES2547127T3 (hr) |
| HK (1) | HK1161122A1 (hr) |
| HR (3) | HRP20150949T1 (hr) |
| HU (4) | HUE028336T2 (hr) |
| LT (1) | LT2392336T (hr) |
| ME (3) | ME02544B (hr) |
| NO (1) | NO340318B1 (hr) |
| PL (4) | PL2392335T3 (hr) |
| PT (3) | PT2392336T (hr) |
| RS (3) | RS54185B1 (hr) |
| SI (4) | SI2392335T1 (hr) |
| WO (1) | WO2006119803A1 (hr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080275030A1 (en) | 2007-01-19 | 2008-11-06 | Sveinbjorn Gizurarson | Methods and Compositions for the Delivery of a Therapeutic Agent |
| US20100311708A1 (en) * | 2007-07-25 | 2010-12-09 | Tarek Moustafa | Use of nor-bile acids in the treatment of arteriosclerosis |
| EP2468762A1 (en) * | 2010-11-30 | 2012-06-27 | Dr. Falk Pharma Gmbh | Optimized synthesis of pure, non-polymorphic, crystalline bile acids with defined particle size |
| EP3461485A1 (en) | 2017-09-28 | 2019-04-03 | Dr. Falk Pharma Gmbh | Use of nor-ursodeoxycholic acid for reducing liver fat |
| GB201911821D0 (en) | 2019-08-16 | 2019-10-02 | Provost Fellows Found Scholars And The Other Members Of Board Of The College Of The Holy And Undivid | Compounds for use in the treatment of liver disease |
| US11372809B2 (en) * | 2019-09-27 | 2022-06-28 | Oracle International Corporation | System and method for providing correlated content organization in an enterprise content management system based on a training set |
| WO2021130232A1 (en) | 2019-12-23 | 2021-07-01 | Medizinische Universität Wien | Bile acid derivatives in the medical intervention of anxieties and/or stress symptoms |
| WO2024023669A1 (en) * | 2022-07-25 | 2024-02-01 | Shilpa Medicare Limited | Pharmaceutical compositions of nor-udca |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4892868A (en) | 1984-08-17 | 1990-01-09 | Gipharmex, S.P.A. | Derivatives of biliary acids, process for the production thereof and corresponding pharmaceutical compositions |
| IT1229569B (it) * | 1989-04-17 | 1991-09-04 | Giuliani Spa | Derivati di acidi biliari, loro preparazione e composizioni farmaceutiche che li contengono. |
| IT1255449B (it) | 1992-06-30 | 1995-10-31 | Fabio Berlati | Uso di nor- e omo-derivati di acidi biliari come promotori di assorbimento di farmaci. |
| TW289020B (hr) | 1993-05-08 | 1996-10-21 | Hoechst Sktiengesellschaft | |
| ITMI20012572A1 (it) | 2001-12-06 | 2003-06-06 | Istituto Biochimico Italiano | Microgranuli di acido ursodesossicolico |
-
2005
- 2005-05-12 PT PT111762712T patent/PT2392336T/pt unknown
- 2005-05-12 PL PL11176270T patent/PL2392335T3/pl unknown
- 2005-05-12 HU HUE05749537A patent/HUE028336T2/en unknown
- 2005-05-12 SI SI200531997T patent/SI2392335T1/sl unknown
- 2005-05-12 ES ES11176270.4T patent/ES2547127T3/es active Active
- 2005-05-12 PT PT111762704T patent/PT2392335E/pt unknown
- 2005-05-12 ME MEP-2016-228A patent/ME02544B/me unknown
- 2005-05-12 PL PL05749537T patent/PL1890705T3/pl unknown
- 2005-05-12 ES ES11176272.0T patent/ES2550204T3/es active Active
- 2005-05-12 HU HUE11176271A patent/HUE030010T2/en unknown
- 2005-05-12 WO PCT/EP2005/052178 patent/WO2006119803A1/en active Application Filing
- 2005-05-12 PT PT111762720T patent/PT2392337E/pt unknown
- 2005-05-12 RS RS20150511A patent/RS54185B1/en unknown
- 2005-05-12 EP EP11176270.4A patent/EP2392335B1/en active Active
- 2005-05-12 PL PL11176272T patent/PL2392337T3/pl unknown
- 2005-05-12 SI SI200532003T patent/SI2392337T1/sl unknown
- 2005-05-12 EP EP05749537.6A patent/EP1890705B1/en active Active
- 2005-05-12 ME MEP-2015-495A patent/ME02737B/me unknown
- 2005-05-12 DK DK11176272.0T patent/DK2392337T3/en active
- 2005-05-12 SI SI200532092A patent/SI2392336T1/sl unknown
- 2005-05-12 HU HUE11176272A patent/HUE025409T2/en unknown
- 2005-05-12 PL PL11176271.2T patent/PL2392336T3/pl unknown
- 2005-05-12 RS RS20150495A patent/RS54140B1/en unknown
- 2005-05-12 DK DK05749537.6T patent/DK1890705T3/en active
- 2005-05-12 DK DK11176270.4T patent/DK2392335T3/da active
- 2005-05-12 ES ES05749537.6T patent/ES2561614T3/es active Active
- 2005-05-12 ES ES11176271.2T patent/ES2590333T3/es active Active
- 2005-05-12 RS RS20160771A patent/RS55180B1/sr unknown
- 2005-05-12 EA EA200702336A patent/EA014077B1/ru not_active IP Right Cessation
- 2005-05-12 ME MEP-2016-198A patent/ME02256B/me unknown
- 2005-05-12 AU AU2005331734A patent/AU2005331734B2/en not_active Ceased
- 2005-05-12 HU HUE11176270A patent/HUE025184T2/en unknown
- 2005-05-12 EP EP11176272.0A patent/EP2392337B1/en active Active
- 2005-05-12 SI SI200532036T patent/SI1890705T1/sl unknown
- 2005-05-12 LT LTEP11176271.2T patent/LT2392336T/lt unknown
- 2005-05-12 DK DK11176271.2T patent/DK2392336T3/en active
- 2005-05-12 EP EP11176271.2A patent/EP2392336B1/en active Active
- 2005-05-12 US US11/914,211 patent/US8951995B2/en active Active
-
2007
- 2007-12-12 NO NO20076405A patent/NO340318B1/no not_active IP Right Cessation
-
2012
- 2012-02-24 HK HK12101926.3A patent/HK1161122A1/xx not_active IP Right Cessation
-
2015
- 2015-09-08 HR HRP20150949TT patent/HRP20150949T1/hr unknown
- 2015-09-23 CY CY20151100834T patent/CY1116831T1/el unknown
- 2015-10-16 HR HRP20151091TT patent/HRP20151091T1/hr unknown
- 2015-10-21 CY CY20151100939T patent/CY1116840T1/el unknown
-
2016
- 2016-02-10 CY CY20161100107T patent/CY1117174T1/el unknown
- 2016-09-02 CY CY20161100863T patent/CY1117959T1/el unknown
- 2016-09-19 HR HRP20161197TT patent/HRP20161197T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20151091T1 (hr) | UPORABA 24-norUDCA | |
| TW200738241A (en) | Pyridazine derivatives | |
| GEP20125701B (en) | Application of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2h-pyrimidin-1-ylmethyl]-4-fluoro-benzonitrile | |
| TW200608972A (en) | Aryl-pyridine derivatives | |
| SG148178A1 (en) | Indozolone derivatives as 11b-hsd1 inhibitors | |
| UY28958A1 (es) | Nuevos derivados de piridazin-3(2h)-ona | |
| WO2008022256A3 (en) | Methods and compositions for preventing or treating age-related diseases | |
| EP2638905A3 (en) | Biofilm treatment | |
| MX2008011633A (es) | Aminoquinolonas como inhibidores de gsk-3. | |
| WO2008124505A3 (en) | Soluble guanylate cyclase (sgc) modulators for treatment of lipid related disorders | |
| WO2008157537A3 (en) | Compositions and methods of use for treating or preventing lipid related disorders | |
| RS52867B (en) | GLATIRAMER ACETATOM AND RAZAGILIN COMBINED THERAPY FOR MULTIPLE SCLEROSIS | |
| TNSN07263A1 (en) | Substituted 4-phenyl tetrahydroisoquinolines, methods for producing them, their use as drug, and drug containing them | |
| ECSP10010052A (es) | Formulaciones galenicas de alisquireno y valsartan | |
| ATE505203T1 (de) | Pharmazeutische kombination aus aliskiren und valsartan | |
| MX2008016426A (es) | Derivados de alquilpiridazina como inhibidores de 11 beta hidroxiesteroide deshidrogenasa tipo 1(11b-hsd 1). | |
| WO2008075320A3 (en) | Antilipidemic pharmaceutical compositions and process for preparation thereof | |
| WO2007131070A3 (en) | Compositions, dosage forms and methods of treating emesis | |
| WO2008008882A3 (en) | Glucocorticoid receptor modulator and methods of use | |
| JP2007119497A5 (hr) | ||
| WO2007133796A3 (en) | Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist | |
| DE602005021115D1 (de) | Verfahren und zusammensetzungen zur oralen fts-abgabe | |
| MX2010004513A (es) | Proceso de obtencion de un extracto estandarizado, extracto obtenido, composicion farmaceutica, metodo de tratamiento y uso de dicho extracto. | |
| WO2007146375A3 (en) | Highly soluble pyrimido-dione-quinoline compounds and their use in the treatment of cancer | |
| WO2009045054A3 (en) | A composition for treatment of conjunctivitis comprising chlorogenic acid and derivatives thereof |